Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Blockade of VEGF alone is sufficient to prevent blinding illness

Feb. 21, 2000

Novel Merck compounds inhibit KDR kinase and VEGF activity

Feb. 15, 2000

Ophthalmic antibacterial on the way to market in Japan

Feb. 15, 2000

FDA issues approvable letter for Visudyne

Feb. 14, 2000

New ophthalmic gene licensed by InSite

Feb. 10, 2000

Oculex updates intraocular drug delivery pipeline

Feb. 4, 2000

Visudyne market introduction announced

Feb. 2, 2000

Are cannabinoid receptors involved in the IOP-lowering effects of cannabinoids?

Feb. 2, 2000

InSite Vision licenses novel TIGR modifier gene

Feb. 2, 2000

Alcon makes milestone payment to Pharmacyclics for Optrin

Feb. 1, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.